Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants.

<h4>Background</h4>Daily nevirapine (NVP) prophylaxis to HIV-exposed infants significantly reduces breast-milk HIV transmission. We assessed NVP-resistance in Indian infants enrolled in the "six-week extended-dose nevirapine" (SWEN) trial who received single-dose NVP (SD-NVP) o...

Full description

Saved in:
Bibliographic Details
Main Authors: Anitha Moorthy, Amita Gupta, Ramesh Bhosale, Srikanth Tripathy, Jayagowri Sastry, Smita Kulkarni, Madhuri Thakar, Renu Bharadwaj, Anju Kagal, Arvind V Bhore, Sandesh Patil, Vandana Kulkarni, Varadharajan Venkataramani, Usha Balasubramaniam, Nishi Suryavanshi, Carrie Ziemniak, Nikhil Gupte, Robert Bollinger, Deborah Persaud
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2009-01-01
Series:PLoS ONE
Online Access:https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0004096&type=printable
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849687096492556288
author Anitha Moorthy
Amita Gupta
Ramesh Bhosale
Srikanth Tripathy
Jayagowri Sastry
Smita Kulkarni
Madhuri Thakar
Renu Bharadwaj
Anju Kagal
Arvind V Bhore
Sandesh Patil
Vandana Kulkarni
Varadharajan Venkataramani
Usha Balasubramaniam
Nishi Suryavanshi
Carrie Ziemniak
Nikhil Gupte
Robert Bollinger
Deborah Persaud
author_facet Anitha Moorthy
Amita Gupta
Ramesh Bhosale
Srikanth Tripathy
Jayagowri Sastry
Smita Kulkarni
Madhuri Thakar
Renu Bharadwaj
Anju Kagal
Arvind V Bhore
Sandesh Patil
Vandana Kulkarni
Varadharajan Venkataramani
Usha Balasubramaniam
Nishi Suryavanshi
Carrie Ziemniak
Nikhil Gupte
Robert Bollinger
Deborah Persaud
author_sort Anitha Moorthy
collection DOAJ
description <h4>Background</h4>Daily nevirapine (NVP) prophylaxis to HIV-exposed infants significantly reduces breast-milk HIV transmission. We assessed NVP-resistance in Indian infants enrolled in the "six-week extended-dose nevirapine" (SWEN) trial who received single-dose NVP (SD-NVP) or SWEN for prevention of breast-milk HIV transmission but who also acquired subtype C HIV infection during the first year of life.<h4>Methods/findings</h4>Standard population sequencing and cloning for viral subpopulations present at > or =5% frequency were used to determine HIV genotypes from 94% of the 79 infected Indian infants studied. Timing of infection was defined based on when an infant's blood sample first tested positive for HIV DNA. SWEN-exposed infants diagnosed with HIV by six weeks of age had a significantly higher prevalence of NVP-resistance than those who received SD-NVP, by both standard population sequencing (92% of 12 vs. 38% of 29; p = 0.002) and low frequency clonal analysis (92% of 12 vs. 59% of 29; p = 0.06). Likelihood of infection with NVP-resistant HIV through breast-milk among infants infected after age six weeks was substantial, but prevalence of NVP-resistance did not differ among SWEN or SD-NVP exposed infants by standard population sequencing (15% of 13 vs. 15% of 20; p = 1.00) and clonal analysis (31% of 13 vs. 40% of 20; p = 0.72). Types of NVP-resistance mutations and patterns of persistence at one year of age were similar between the two groups. NVP-resistance mutations did differ by timing of HIV infection; the Y181C variant was predominant among infants diagnosed in the first six weeks of life, compared to Y188C/H during late breast-milk transmission.<h4>Conclusions/significance</h4>Use of SWEN to prevent breast-milk HIV transmission carries a high likelihood of resistance if infection occurs in the first six weeks of life. Moreover, there was a continued risk of transmission of NVP-resistant HIV through breastfeeding during the first year of life, but did not differ between SD-NVP and SWEN groups. As with SD-NVP, the value of preventing HIV infection in a large number of infants should be considered alongside the high risk of resistance associated with extended NVP prophylaxis.<h4>Trial registration</h4>ClinicalTrials.gov NCT00061321.
format Article
id doaj-art-372edef596d84d8e929a438ed6608388
institution DOAJ
issn 1932-6203
language English
publishDate 2009-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj-art-372edef596d84d8e929a438ed66083882025-08-20T03:22:26ZengPublic Library of Science (PLoS)PLoS ONE1932-62032009-01-0141e409610.1371/journal.pone.0004096Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants.Anitha MoorthyAmita GuptaRamesh BhosaleSrikanth TripathyJayagowri SastrySmita KulkarniMadhuri ThakarRenu BharadwajAnju KagalArvind V BhoreSandesh PatilVandana KulkarniVaradharajan VenkataramaniUsha BalasubramaniamNishi SuryavanshiCarrie ZiemniakNikhil GupteRobert BollingerDeborah Persaud<h4>Background</h4>Daily nevirapine (NVP) prophylaxis to HIV-exposed infants significantly reduces breast-milk HIV transmission. We assessed NVP-resistance in Indian infants enrolled in the "six-week extended-dose nevirapine" (SWEN) trial who received single-dose NVP (SD-NVP) or SWEN for prevention of breast-milk HIV transmission but who also acquired subtype C HIV infection during the first year of life.<h4>Methods/findings</h4>Standard population sequencing and cloning for viral subpopulations present at > or =5% frequency were used to determine HIV genotypes from 94% of the 79 infected Indian infants studied. Timing of infection was defined based on when an infant's blood sample first tested positive for HIV DNA. SWEN-exposed infants diagnosed with HIV by six weeks of age had a significantly higher prevalence of NVP-resistance than those who received SD-NVP, by both standard population sequencing (92% of 12 vs. 38% of 29; p = 0.002) and low frequency clonal analysis (92% of 12 vs. 59% of 29; p = 0.06). Likelihood of infection with NVP-resistant HIV through breast-milk among infants infected after age six weeks was substantial, but prevalence of NVP-resistance did not differ among SWEN or SD-NVP exposed infants by standard population sequencing (15% of 13 vs. 15% of 20; p = 1.00) and clonal analysis (31% of 13 vs. 40% of 20; p = 0.72). Types of NVP-resistance mutations and patterns of persistence at one year of age were similar between the two groups. NVP-resistance mutations did differ by timing of HIV infection; the Y181C variant was predominant among infants diagnosed in the first six weeks of life, compared to Y188C/H during late breast-milk transmission.<h4>Conclusions/significance</h4>Use of SWEN to prevent breast-milk HIV transmission carries a high likelihood of resistance if infection occurs in the first six weeks of life. Moreover, there was a continued risk of transmission of NVP-resistant HIV through breastfeeding during the first year of life, but did not differ between SD-NVP and SWEN groups. As with SD-NVP, the value of preventing HIV infection in a large number of infants should be considered alongside the high risk of resistance associated with extended NVP prophylaxis.<h4>Trial registration</h4>ClinicalTrials.gov NCT00061321.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0004096&type=printable
spellingShingle Anitha Moorthy
Amita Gupta
Ramesh Bhosale
Srikanth Tripathy
Jayagowri Sastry
Smita Kulkarni
Madhuri Thakar
Renu Bharadwaj
Anju Kagal
Arvind V Bhore
Sandesh Patil
Vandana Kulkarni
Varadharajan Venkataramani
Usha Balasubramaniam
Nishi Suryavanshi
Carrie Ziemniak
Nikhil Gupte
Robert Bollinger
Deborah Persaud
Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants.
PLoS ONE
title Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants.
title_full Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants.
title_fullStr Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants.
title_full_unstemmed Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants.
title_short Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants.
title_sort nevirapine resistance and breast milk hiv transmission effects of single and extended dose nevirapine prophylaxis in subtype c hiv infected infants
url https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0004096&type=printable
work_keys_str_mv AT anithamoorthy nevirapineresistanceandbreastmilkhivtransmissioneffectsofsingleandextendeddosenevirapineprophylaxisinsubtypechivinfectedinfants
AT amitagupta nevirapineresistanceandbreastmilkhivtransmissioneffectsofsingleandextendeddosenevirapineprophylaxisinsubtypechivinfectedinfants
AT rameshbhosale nevirapineresistanceandbreastmilkhivtransmissioneffectsofsingleandextendeddosenevirapineprophylaxisinsubtypechivinfectedinfants
AT srikanthtripathy nevirapineresistanceandbreastmilkhivtransmissioneffectsofsingleandextendeddosenevirapineprophylaxisinsubtypechivinfectedinfants
AT jayagowrisastry nevirapineresistanceandbreastmilkhivtransmissioneffectsofsingleandextendeddosenevirapineprophylaxisinsubtypechivinfectedinfants
AT smitakulkarni nevirapineresistanceandbreastmilkhivtransmissioneffectsofsingleandextendeddosenevirapineprophylaxisinsubtypechivinfectedinfants
AT madhurithakar nevirapineresistanceandbreastmilkhivtransmissioneffectsofsingleandextendeddosenevirapineprophylaxisinsubtypechivinfectedinfants
AT renubharadwaj nevirapineresistanceandbreastmilkhivtransmissioneffectsofsingleandextendeddosenevirapineprophylaxisinsubtypechivinfectedinfants
AT anjukagal nevirapineresistanceandbreastmilkhivtransmissioneffectsofsingleandextendeddosenevirapineprophylaxisinsubtypechivinfectedinfants
AT arvindvbhore nevirapineresistanceandbreastmilkhivtransmissioneffectsofsingleandextendeddosenevirapineprophylaxisinsubtypechivinfectedinfants
AT sandeshpatil nevirapineresistanceandbreastmilkhivtransmissioneffectsofsingleandextendeddosenevirapineprophylaxisinsubtypechivinfectedinfants
AT vandanakulkarni nevirapineresistanceandbreastmilkhivtransmissioneffectsofsingleandextendeddosenevirapineprophylaxisinsubtypechivinfectedinfants
AT varadharajanvenkataramani nevirapineresistanceandbreastmilkhivtransmissioneffectsofsingleandextendeddosenevirapineprophylaxisinsubtypechivinfectedinfants
AT ushabalasubramaniam nevirapineresistanceandbreastmilkhivtransmissioneffectsofsingleandextendeddosenevirapineprophylaxisinsubtypechivinfectedinfants
AT nishisuryavanshi nevirapineresistanceandbreastmilkhivtransmissioneffectsofsingleandextendeddosenevirapineprophylaxisinsubtypechivinfectedinfants
AT carrieziemniak nevirapineresistanceandbreastmilkhivtransmissioneffectsofsingleandextendeddosenevirapineprophylaxisinsubtypechivinfectedinfants
AT nikhilgupte nevirapineresistanceandbreastmilkhivtransmissioneffectsofsingleandextendeddosenevirapineprophylaxisinsubtypechivinfectedinfants
AT robertbollinger nevirapineresistanceandbreastmilkhivtransmissioneffectsofsingleandextendeddosenevirapineprophylaxisinsubtypechivinfectedinfants
AT deborahpersaud nevirapineresistanceandbreastmilkhivtransmissioneffectsofsingleandextendeddosenevirapineprophylaxisinsubtypechivinfectedinfants